A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

223 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-01

Study Completion Date

2013-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

NCT02294396

Overactive Bladder (OAB)

COMPLETED PHASE4

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

NCT01638000

Urologic Diseases Urinary Bladder, Overactive Urinary Bladder Diseases

COMPLETED PHASE3

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

NCT01340027

Urologic Diseases Urinary Bladder Diseases Urological Manifestations +2 more

COMPLETED PHASE2

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862

Urinary Bladder Overactive Overactive Bladder Urgency Incontinence +1 more

COMPLETED PHASE3

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

NCT04693897

Overactive Bladder Syndrome Detrusor Overactivity

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The total duration of the study was 18 weeks, comprising a 2-week screening period and a 16-week treatment period. Patients meeting the eligibility criteria for provisional enrollment received the study drug for the screening period (solifenacin) at the same dose as that before the start of the study (2.5 or 5 mg), once daily after breakfast orally for 2 weeks. After the screening period, patients meeting the eligibility criteria for formal enrollment received the study drugs for the treatment period (solifenacin 2.5 or 5 mg and mirabegron 25 mg), once daily after breakfast orally for 16 weeks. Mirabegron dose could be increased to 50 mg at week 8 visit if the patients met all of the following criteria: (1) had an inadequate response to mirabegron at the dose of 25 mg; (2) was judged by the investigator or coinvestigator to have no safety concerns; and (3) agreed to increase the dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Concomitant Group

concomitant administration of mirabegron to solifenacin treated patients

Group Type EXPERIMENTAL

mirabegron

Intervention Type DRUG

oral

solifenacin

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mirabegron

oral

Intervention Type DRUG

solifenacin

oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

YM178 Betanis Vesicare YM905

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female: postmenopausal OAB outpatient
* Male: OAB outpatient who did not wish to have children at all
* Patient had been treated with solifenacin at a stable dose once daily for at least 4 weeks prior to the study
* Patient had a total OAB symptom score (OABSS ) score of ≥3 points and a Question 3 score ≥2 points

Exclusion Criteria

* Patient had a residual urine volume of ≥100 mL or a maximum flow rate \<5 mL/s, or patients with benign prostatic hyperplasia, or lower urinary tract obstruction
* Patient had serious heart disease (myocardial infarction, cardiac failure, uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver disease, kidney disease, immunological disease, lung disease, etc. or patient had malignant tumor (except for malignant tumor that has not been treated for at least 5 y before the start of the screening period with no risk of recurrence)
* Patient had received surgical therapy that may affect the urinary tract function within 24 weeks before the start of the screening period

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No